Dong Z, Ojha A, Barlow L, Luo L, Liu J, Zhang J
Cancer Lett. 2024; 605:217303.
PMID: 39413959
PMC: 11646415.
DOI: 10.1016/j.canlet.2024.217303.
Sehrawat U
Int J Mol Sci. 2024; 25(19).
PMID: 39409166
PMC: 11477148.
DOI: 10.3390/ijms251910835.
Huo C, Wu D, Li X, Zhang Y, Hu B, Zhang T
Cancer Biol Ther. 2024; 25(1):2355703.
PMID: 38782896
PMC: 11123456.
DOI: 10.1080/15384047.2024.2355703.
Huang R, Nie W, Mi L, Yao C, Zhu H
Aging (Albany NY). 2024; 16(8):7311-7330.
PMID: 38687509
PMC: 11087095.
DOI: 10.18632/aging.205759.
Mei C, Sun Z, Tan L, Gong J, Li X, Liu Z
Cell Prolif. 2022; 55(4):e13208.
PMID: 35187743
PMC: 9055905.
DOI: 10.1111/cpr.13208.
Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma.
Zhang Y, Hua X, Shi H, Zhang L, Xiao H, Liang C
Cancer Cell Int. 2021; 21(1):680.
PMID: 34923969
PMC: 8684683.
DOI: 10.1186/s12935-021-02364-2.
An eIF3a gene mutation dysregulates myocardium growth with left ventricular noncompaction via the p-ERK1/2 pathway.
Ge M, Bai X, Liu A, Liu L, Tian J, Lu T
Genes Dis. 2021; 8(4):545-554.
PMID: 34179316
PMC: 8209309.
DOI: 10.1016/j.gendis.2020.02.003.
Interactome Mapping of eIF3A in a Colon Cancer and an Immortalized Embryonic Cell Line Using Proximity-Dependent Biotin Identification.
Vo D, Engler A, Stoimenovski D, Hartig R, Kaehne T, Kalinski T
Cancers (Basel). 2021; 13(6).
PMID: 33799492
PMC: 7999522.
DOI: 10.3390/cancers13061293.
eIF3a Regulation of NHEJ Repair Protein Synthesis and Cellular Response to Ionizing Radiation.
Tumia R, Wang C, Dong T, Ma S, Beebe J, Chen J
Front Cell Dev Biol. 2020; 8:753.
PMID: 32974334
PMC: 7466773.
DOI: 10.3389/fcell.2020.00753.
Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas.
Kelemen O, Pla I, Sanchez A, Rezeli M, Szasz A, Malm J
Clin Transl Med. 2020; 10(2):e106.
PMID: 32536039
PMC: 7403673.
DOI: 10.1002/ctm2.106.
Array Comparative Genomic Hybridization Analysis Reveals Significantly Enriched Pathways in Canine Oral Melanoma.
Brocca G, Ferraresso S, Zamboni C, Martinez-Merlo E, Ferro S, Goldschmidt M
Front Oncol. 2020; 9:1397.
PMID: 31921654
PMC: 6920211.
DOI: 10.3389/fonc.2019.01397.
Overexpression of in Lung Adenocarcinoma Is a New Independent Prognostic Marker of Poor Survival.
Wang D, Jia Y, Zheng W, Li C, Cui W
Dis Markers. 2019; 2019:6019637.
PMID: 31885740
PMC: 6925810.
DOI: 10.1155/2019/6019637.
eIF3a mediates HIF1α-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation.
Miao B, Wei C, Qiao Z, Han W, Chai X, Lu J
Am J Cancer Res. 2019; 9(5):1079-1090.
PMID: 31218114
PMC: 6556603.
Translation regulation in skin cancer from a tRNA point of view.
Grafanaki K, Anastasakis D, Kyriakopoulos G, Skeparnias I, Georgiou S, Stathopoulos C
Epigenomics. 2018; 11(2):215-245.
PMID: 30565492
PMC: 6391632.
DOI: 10.2217/epi-2018-0176.
eIF3: a factor for human health and disease.
Gomes-Duarte A, Lacerda R, Menezes J, Romao L
RNA Biol. 2017; 15(1):26-34.
PMID: 29099306
PMC: 5785978.
DOI: 10.1080/15476286.2017.1391437.
EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3K-AKT signaling pathway.
Zhang F, Xiang S, Cao Y, Li M, Ma Q, Liang H
Cell Death Dis. 2017; 8(6):e2868.
PMID: 28594409
PMC: 5520919.
DOI: 10.1038/cddis.2017.263.
Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells.
Choi Y, Lee Y, Lee H, Shim D, Seo S
Bone Joint Res. 2017; 6(3):186-193.
PMID: 28360085
PMC: 5376660.
DOI: 10.1302/2046-3758.63.BJR-2016-0151.R2.
MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C, Chen Y, Wu N, Yin J, Li X, Huang H
Sci Rep. 2017; 7:40384.
PMID: 28074905
PMC: 5225486.
DOI: 10.1038/srep40384.
Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.
Young J, Peyton M, Kim H, McMillan E, Minna J, White M
Bioinformatics. 2016; 32(9):1373-9.
PMID: 26755624
PMC: 4848405.
DOI: 10.1093/bioinformatics/btw010.
eIF3 controls cell size independently of S6K1-activity.
Schipany K, Rosner M, Ionce L, Hengstschlager M, Kovacic B
Oncotarget. 2015; 6(27):24361-75.
PMID: 26172298
PMC: 4695191.
DOI: 10.18632/oncotarget.4458.